Antidepressant Potential of ()-Ketamine in Rodent Models: Comparison with ()-Ketamine
Overview
Authors
Affiliations
The rapid-acting and long-lasting antidepressant effects of ()-ketamine have recently gained much attention. Although ()-ketamine has been studied as an active isomer, recent evidence suggests that ()-ketamine exhibits longer-lasting antidepressant effects than ()-ketamine in rodents. However, the antidepressant potential of ()-ketamine has not been fully addressed. In the present study, we compared the antidepressant effects of ()-ketamine with those of ()-ketamine in animal models of depression, including a model that is refractory to current medications. Both ()-ketamine and ()-ketamine exhibited antidepressant effects at 30 minutes as well as at 24 hours after administration in forced-swimming and tail-suspension tests in mice. At 48 hours after administration, however, ()-ketamine still exerted a significant antidepressant effect in the tail-suspension test, whereas the effect of ()-ketamine was no longer observed. Moreover, ()-ketamine, but not ()-ketamine, significantly reversed the depressive-like behavior induced by repeated treatments with corticosterone in rats at 24 hours after a single administration. This effect was attenuated by an -amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptor antagonist, suggesting the involvement of AMPA receptor stimulation in the effects. Both ()-ketamine and ()-ketamine exhibited practically the same exposure levels in plasma, brain, and cerebrospinal fluid in mice and rats, and both compounds were rapidly eliminated from plasma (<4-8 hours). The present results confirmed the previous findings that ()-ketamine exerted longer-lasting antidepressant effects than ()-ketamine in animal models of depression. Moreover, our study is the first to demonstrate that ()-ketamine exerted a sustained antidepressant effect even in a model that is refractory to currently prescribed antidepressants.
Rizzo A, Garcon-Poca M, Essmann A, Souza A, Michaelides M, Ciruela F Mol Psychiatry. 2025; .
PMID: 39972056 DOI: 10.1038/s41380-025-02931-3.
Sajid S, Mann J, Grunebaum M Transl Psychiatry. 2025; 15(1):44.
PMID: 39915491 PMC: 11802767. DOI: 10.1038/s41398-025-03255-0.
Moura C, de Sousa-Silva A, Soares A, de Oliveira Torres C, Belchior H, da Silva Jr E Brain Sci. 2025; 14(12.
PMID: 39766490 PMC: 11674349. DOI: 10.3390/brainsci14121291.
Assessment of Ketamine's Influence on In Vitro Angiogenesis.
Takaishi K, Takata M, Nishikawa M, Kitahata H, Kawahito S Anesth Prog. 2024; 71(4):176-182.
PMID: 39711454 PMC: 11614467. DOI: 10.2344/23-0011.
Arketamine: a scoping review of its use in humans.
Leal G, Lima-Araujo I, Roiter D, Caliman-Fontes A, Mello R, Kapczinski F Eur Arch Psychiatry Clin Neurosci. 2024; .
PMID: 39680139 DOI: 10.1007/s00406-024-01945-2.